On a corporate action affecting ordinary shares of Mirati Therapeutics, Inc. (MRTX)

On October 08, 2023, Mirati Therapeutics, Inc. signed a merger agreement with Bristol-Myers Squibb Company under which Bristol-Myers Squibb Company will acquire Mirati Therapeutics, Inc. for $58.00 and one contingent value right representing the right to receive $12.00 in cash per share. For more details, please, refer to the company’s website.

ITS Ltd. will publish separate notices on the procedures undertaken by ITS Ltd. to process this corporate action outlining how trading in these qualified investments will be carried out.